{
  "documentMetadata": {
    "title": "Pneumonia, Hospital-Acquired, Overview",
    "sourceFile": "Pneumonia, Hospital-Acquired, Overview.pdf",
    "lastUpdated": "2025-02-09"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Overview"
    },
    {
      "type": "list",
      "items": [
        "Overview of treatment of pneumonia caused by hospital-acquired bacteria. Nosocomial pneumonia.",
        "2016 IDSA Guidelines: (Clin Infect Dis 2016; 63:e61)",
        "2017 European Guidelines: (Eur Respir J 2017; 50:1700582)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Duration of therapy",
        "In general treat for 7-8 days",
        "Whether a longer duration of therapy should be used for pneumonia caused by non-fermenting organisms (e.g., Pseudomonas aeruginosa) or multiple-drug resistant Gram-negatives continues to be debated (See Clin Infect Disease 2023; 76:745 and Clin Infect Dis 2023; 76:750).",
        "Longer durations of therapy, e.g., 10-14 days, may be appropriate in certain circumstances:",
        "Infections caused by more resistant pathogens (e.g., Pseudomonas, Acinetobacter, Stenotrophomonas, or other multidrug-resistant pathogens), particularly in patients with underlying ARDS or significant structural lung disease",
        "Severely immunocompromised hosts (e.g. recent organ transplantation or treatment for rejection within 3 months, congenital immunodeficiency, etc).",
        "Presence of complications such as bacteremia (e.g., MRSA or MSSA pneumonia with bacteremia probably should be treated for 4 weeks) or empyema.",
        "Delayed improvement of clinical, radiologic, and/or laboratory parameters.",
        "Empiric regimen of choice varies with institution or clinical setting depending upon local epidemiology, local susceptibility patterns, known prior colonization with multidrug-resistant (MDR) organisms, prior treatment history, severity of illness.",
        "Improved outcome is associated with initial appropriate antibiotic treatment (i.e., at least one active agent); if MDR pathogens are suspected, initial coverage should be broad and then de-escalated once culture and susceptibility results become available."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Specific Topics"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "header",
          "level": 2,
          "text": "Empiric Therapy"
        },
        {
          "type": "list",
          "items": [
            "Gram-negative pneumonia in the ICU",
            "Adult, out-patient/non-hospitalized",
            "Adult, in-patient/hospitalized",
            "Hospital-acquired pneumonia",
            "Pneumonia, neutropenic patient",
            "Ventilator associated pneumonia"
          ]
        },
        {
          "type": "header",
          "level": 2,
          "text": "Specific Therapy"
        },
        {
          "type": "list",
          "items": [
            "Acinetobacter pneumonia",
            "Klebsiella pneumonia",
            "Legionella pneumonia",
            "Pseudomonas pneumonia",
            "Staph. aureus pneumonia",
            "Stenotrophomonas pneumonia"
          ]
        }
      ]
    }
  ]
}